BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36380705)

  • 1. Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib.
    Qiu X; Ren B; Lian Y; Fang L; Dong Z
    J Oncol Pharm Pract; 2023 Jun; 29(4):1002-1005. PubMed ID: 36380705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report.
    Qiao F; Chen Q; Lu W; Fang N
    Medicine (Baltimore); 2022 Jul; 101(27):e29629. PubMed ID: 35801736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.
    Rabinovich-Guilatt L; Steiner L; Hallak H; Pastino G; Muglia P; Spiegelstein O
    Br J Clin Pharmacol; 2017 Oct; 83(10):2214-2224. PubMed ID: 28449367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
    Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
    J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP2D6 Genetic Polymorphism and Drug Interaction on the Metabolism of Dacomitinib.
    Han M; Zhang X; Ye Z; Wang J; Kong Q; Hu X; Qian J; Cai J; Hu G
    Chem Res Toxicol; 2022 Feb; 35(2):265-274. PubMed ID: 34936353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.
    Gedde-Dahl A; Spigset O; Molden E
    Eur J Clin Pharmacol; 2022 Oct; 78(10):1623-1632. PubMed ID: 35871665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.
    Anstensrud AK; Molden E; Haug HJ; Qazi R; Muriq H; Fosshaug LE; Spigset O; Øie E
    Eur J Clin Pharmacol; 2020 May; 76(5):673-683. PubMed ID: 31940084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism-Based Inactivation of CYP2D6 by Phellopterin and Related Drug-Drug Interaction with Metoprolol.
    Cheng Z; He Y; Chen Y; Zhao G; Liu Y; Zhang J; Li X; Ran G; Zhang Q; Peng Y; Li W; Zheng J
    J Agric Food Chem; 2024 Jan; 72(3):1745-1755. PubMed ID: 38214270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
    Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
    Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
    Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.
    Zhou T; Xiong Q; Hong C; Wang Q; Wang W; Xu C; Cai J;
    Medicine (Baltimore); 2022 Aug; 101(34):e30269. PubMed ID: 36042660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced oral bioavailability of metoprolol with gallic acid and ellagic acid in male Wistar rats: involvement of CYP2D6 inhibition.
    Athukuri BL; Neerati P
    Drug Metab Pers Ther; 2016 Dec; 31(4):229-234. PubMed ID: 27875319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A metoprolol-terbinafine combination induced bradycardia.
    Bebawi E; Jouni SS; Tessier AA; Frenette AJ; Brindamour D; Doré M
    Eur J Drug Metab Pharmacokinet; 2015 Sep; 40(3):295-9. PubMed ID: 24894748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.
    Hamadeh IS; Langaee TY; Dwivedi R; Garcia S; Burkley BM; Skaar TC; Chapman AB; Gums JG; Turner ST; Gong Y; Cooper-DeHoff RM; Johnson JA
    Clin Pharmacol Ther; 2014 Aug; 96(2):175-81. PubMed ID: 24637943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphene.
    Marraffa JM; Lang L; Ong G; Lehmann DF
    Clin Pharmacol Ther; 2006 Mar; 79(3):282-6. PubMed ID: 16513452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS.
    Borkar RM; Bhandi MM; Dubey AP; Ganga Reddy V; Komirishetty P; Nandekar PP; Sangamwar AT; Kamal A; Banerjee SK; Srinivas R
    Biomed Chromatogr; 2016 Oct; 30(10):1556-72. PubMed ID: 27006091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
    Hamelin BA; Bouayad A; Méthot J; Jobin J; Desgagnés P; Poirier P; Allaire J; Dumesnil J; Turgeon J
    Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations.
    Johnson JA; Burlew BS
    Drug Metab Dispos; 1996 Mar; 24(3):350-5. PubMed ID: 8820427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
    Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K
    Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.